RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 85.0% in March

RenovoRx, Inc. (NASDAQ:RNXT – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 62,700 shares, a growth of 85.0% from the March 15th total of 33,900 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 72,400 shares, the short-interest ratio is presently 0.9 days.

Separately, Zacks Investment Research raised shares of RenovoRx from a “sell” rating to a “hold” rating in a report on Friday.

Several large investors have recently bought and sold shares of RNXT. Virtu Financial LLC bought a new position in shares of RenovoRx during the 4th quarter valued at about $64,000. Citadel Advisors LLC bought a new position in shares of RenovoRx during the 3rd quarter valued at about $73,000. Two Sigma Securities LLC bought a new position in shares of RenovoRx during the 3rd quarter valued at about $108,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of RenovoRx in the third quarter worth about $125,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of RenovoRx in the third quarter worth about $247,000. Institutional investors own 1.60% of the company’s stock.

RenovoRx stock traded down $0.12 during trading hours on Friday, hitting $2.59. 81,944 shares of the company traded hands, compared to its average volume of 111,333. The firm’s 50-day simple moving average is $3.20 and its two-hundred day simple moving average is $4.65. RenovoRx has a 1-year low of $2.46 and a 1-year high of $16.74.

RenovoRx (NASDAQ:RNXT – Get Rating) last released its earnings results on Wednesday, March 30th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. Research analysts expect that RenovoRx will post -1 earnings per share for the current fiscal year.

About RenovoRx (Get Rating)

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

Featured Articles